Work

Development of a High-Quality Tag-Free Ubiquitin Production Platform for Preclinical Applications

Year: 2026
Type: article
Abstract: Monomeric ubiquitin (Ub1−76) has shown immunomodulatory properties in a herpes simplex virus type 1 (HSV-1)-infected mouse model when administered orally, positioning it as a promising biotherapeutic agent. Accordingly, preclinical research requires sufficient, high-quality Ub1−76 material. This study focuses on developing an expression and purification platform for Tag-Free Ub1−76 and its variant Ub1−74. Ubs were expressed in Escherichia coli BL21(DE3) cells, released by sonication, and precipitated in pH 4.5 glacial acetic acid. The pH was set to 5.1, and Ubs were purified by Size-Exclusion Chromatography (SEC); the buffer was exchanged via SEC desalting. Then, a polishing step using cation-exchange chromatography (CEX) was applied, which finalized purification with a second buffer exchange via SEC desalting. We independently produced six batches of Ub1−76 and three batches of Ub1−74 using the proposed platform, yielding 109.07 mg/L for each protein. The Quality Control (QC) of the Ubs met the predefined acceptance criteria: purity by SE-UHPLC (>95.0%), concentration by Bicinchoninic Acid (>1.0 mg/mL), endotoxin content by LAL (<10 EU/mg), integrity by SDS-PAGE (single band), mean deconvoluted intact-mass centroid values (8564.40 Da for Ub1−76 and 8451.73 Da for Ub1−74). The Ubs obtained in this study were similar to a commercial Ub1−76 (Ub1−76 com), which was used as an identity reference. We also used circular dichroism (CD) to compare the secondary structure of Ub1−76 com, Ub1−76, and Ub1−74; all showed similar structures. The expression platform described here provides Tag-Free ubiquitin suitable for preclinical feasibility research and a framework for producing peptide and small-protein biotherapeutic candidates.
Language: English
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7236426069
FWCI:
Cites: 41
Cited by:
Related to: 10